| Identification | Back Directory | [Name]
Tenofovir disoproxil | [CAS]
201341-05-1 | [Synonyms]
Tdf
SRY
Aids080741
Aids-080741
Bis(poc)pmpa
Pmpa prodrug
Tenofov ir Disoprox
Tenofovir disoproxil
Testis-determining factor
Tenofovir disoproxil, >=98%
TenofivirDisoproxilFumarate
Tenofovir disoproxil aspartate
202138-50-9 (1:1 Fumarate salt)
Gs 4331-05 (*1:1 fumarate salt*)
Tenofovirdisoproxil(Fumaratesalt)
Bis(isopropyloxymethylcarbonyl)pmpa
9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine
(R)-(((((1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphoryl)-bis(oxy))bis(methylene) d
(R)-(((((1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphoryl)-bis(oxy))bis(methylene) diis
(R)-(((((1-(6-AMino-9H-purin-9-yl)propan-2-yl)oxy)Methyl)phosphoryl)bis(oxy))bis(Methylene) diisopropyl dicarbonate
5-[[(1r)-2-(6-Amino-9h-Purin-9-Yl)-1-Methylethoxy]Methyl]-2,4,6,8-Tetraoxa-5-Phosphanononanedioic Acid Bis(1-Methylethyl) Ester 5-Oxide
2,4,6,8-Tetraoxa-5-phosphanonanedioicacid, 5-[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-,1,9-bis(1-Methylethyl) ester, 5-oxide | [EINECS(EC#)]
111-111-1 | [Molecular Formula]
C19H30N5O10P | [MDL Number]
MFCD00952920 | [MOL File]
201341-05-1.mol | [Molecular Weight]
519.44 |
| Chemical Properties | Back Directory | [Boiling point ]
642.7±65.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: ≥ 38 mg/mL (73.16 mM) | [form ]
Solid | [pka]
4.20±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
JFVZFKDSXNQEJW-CQSZACIVSA-N | [SMILES]
C(OC(C)C)(=O)OCOP(=O)(CO[C@H](C)CN1C2C(N=C1)=C(N)N=CN=2)OCOC(OC(C)C)=O | [CAS DataBase Reference]
201341-05-1 |
| Hazard Information | Back Directory | [Definition]
ChEBI: An organic phosphonate that is the disoproxil ester of tenofovir. A prodrug for tenofovir, an HIV-1 reverse transcriptase inhibitor, tenofovir disoproxil is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. | [Uses]
Tenofovir Disoproxil is a therapeutic option for nucleos(t)ide analog (NA)-experienced chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV). Also, it is an intermediate used in the synthesis of Tenofovir Disoproxil Dimer (T018515), which is a Tenofovir Disoproxil impurity. | [General Description]
Tenofovir disoproxil is a prodrug analogously with abacavir.Plasma and tissue esterases cleave the phosphateprotecting groups, releasing the active drug. The bioavailabilityof tenofovir is about 35% when administered withfood. The drug is approved by the Food and DrugAdministration (FDA) for the treatment of HIV infectionsin adult patients. Recommendations are for the drug to beadministered with other RT inhibitors or PIs to achievesynergism. | [Clinical Use]
Nucleoside reverse transcriptase inhibitor:
Treatment of HIV in combination with other
antiretroviral drugs
Treatment of hepatitis B in compensated liver
disease | [Drug interactions]
Potentially hazardous interactions with other drugs
Antivirals: avoid with adefovir and cidofovir; reduces
concentration of atazanavir, also concentration of
tenofovir possibly increased; increased didanosine
concentration resulting in increased toxicity
(e.g. pancreatitis and lactic acidosis) - avoid;
concentration increased by lopinavir and telaprevir.
Co-administration with other drugs that are actively
secreted via the tubular anionic transporter.
Orlistat: absorption possibly reduced by orlistat. | [Metabolism]
Tenofovir is excreted mainly in the urine by both active
tubular secretion and glomerular filtration. | [storage]
Store at -20°C |
| Questions And Answer | Back Directory | [Description]
Tenofovir disoproxil belongs to a class of medications called antiretroviral known as a nucleotide reverse transcriptase inhibitor, which is commonly used to treat the infection caused by the human immunodeficiency virus (HIV) generally in combination with other antiviral agents. It can also be used for prevention of HIV/AIDS among those people who are at high risk before exposure, such as injection through sexual transmission or injection of drugs. It functions by blocking reverse transcriptase, an enzyme vital to viral duplication in people infected HIV. Besides, it is effective to treat chronic hepatitis B, in which it helps prevent the enzymes needed for the hepatitis B virus to reproduce from working properly. However, tenofovir disoproxil does not cure HIV/AIDS or hepatitis B. It helps lower the amount of HIV or hepatitis B virus in the body and slow down the progression of the disease. Tenofovir was patented in 1996 and approved for use in the United States in 2001.
| [References]
https://en.wikipedia.org/wiki/Tenofovir_disoproxil
http://bodyandhealth.canada.com/drug/getdrug/viread
https://www.drugbank.ca/drugs/DB00300
|
|
| Company Name: |
Eastbang Pharmaceuticals Technology Co., Ltd.
|
| Telephone: |
+86 (20) 28996708,29078958,28139708,29076128,28133708,28139728,28139738,28133718,021-31663278,021-31663578,021-60538387 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList13633/0_EN.htm |
|